351 related articles for article (PubMed ID: 3881560)
41. Adjuvant use of cytotoxic chemotherapy to destroy micrometastasis in breast cancer after local control therapy--current status.
Carter SK
Clin Exp Metastasis; 1983; 1(1):1-15. PubMed ID: 6399695
[No Abstract] [Full Text] [Related]
42. Adjuvant therapy for breast cancer: a brief overview of the NSABP experience and some thoughts on neoadjuvant chemotherapy.
Fisher B
Recent Results Cancer Res; 1986; 103():54-68. PubMed ID: 3526476
[No Abstract] [Full Text] [Related]
43. Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status.
Rivkin SE; Knight WA; McDivitt R; Cruz T; Foulkes M; Osborne CK; Fabian CJ; Costanzi JJ
World J Surg; 1985 Oct; 9(5):723-7. PubMed ID: 3840629
[No Abstract] [Full Text] [Related]
44. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.
Camoriano JK; Loprinzi CL; Ingle JN; Therneau TM; Krook JE; Veeder MH
J Clin Oncol; 1990 Aug; 8(8):1327-34. PubMed ID: 2199619
[TBL] [Abstract][Full Text] [Related]
45. Preoperative chemotherapy in primarily inoperable cancer of the breast.
Luboinski G; Nagadowska M; Pienkowski T
Eur J Surg Oncol; 1991 Dec; 17(6):603-7. PubMed ID: 1743309
[TBL] [Abstract][Full Text] [Related]
46. Adjuvant chemo-endocrine therapy or endocrine therapy alone for postmenopausal patients: Ludwig Studies III and IV.
Goldhirsch A; Gelber RD
Recent Results Cancer Res; 1989; 115():153-62. PubMed ID: 2696027
[No Abstract] [Full Text] [Related]
47. A brief overview of findings from NSABP trials of adjuvant therapy.
Fisher B; Fisher ER; Redmond C
Recent Results Cancer Res; 1984; 96():55-65. PubMed ID: 6101262
[No Abstract] [Full Text] [Related]
48. Randomized multicenter 2 x 2-factorial design study of chemo/endocrine therapy in operable, node-positive breast cancer (protocol 2).
Scheurlen H
Recent Results Cancer Res; 1989; 115():226-35. PubMed ID: 2696037
[No Abstract] [Full Text] [Related]
49. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.
Gelber RD; Goldhirsch A
J Clin Oncol; 1986 Dec; 4(12):1772-9. PubMed ID: 3783203
[TBL] [Abstract][Full Text] [Related]
50. CMF adjuvant programs at the Milan Cancer Institute.
Bonadonna G; Rossi A; Tancini G; Valagussa P; Veronesi U
Recent Results Cancer Res; 1984; 96():66-73. PubMed ID: 6549356
[No Abstract] [Full Text] [Related]
51. Alternating versus sequential therapy in advanced breast cancer.
Romero A; Rabinovich MG; Pérez JE; Macchiavelli M; Leone BA; Strauss E; Goldar D; Alvarez LA; Vallejo C
Medicina (B Aires); 1987; 47(3):243-8. PubMed ID: 3326994
[No Abstract] [Full Text] [Related]
52. Adjuvant systemic treatment of resectable breast cancer: eleven years results of a monoinstitutional chemo-hormone-immunotherapy trial.
Rosso R; Boccardo F; Brema F; Sertoli MR; Amoroso D; Bertelli G; Pronzato P
Anticancer Res; 1989; 9(4):1153-6. PubMed ID: 2817796
[TBL] [Abstract][Full Text] [Related]
53. [Adjuvant endocrine therapy and chemotherapy of breast cancer (author's transl)].
Heuson JC; Paridaens R
Rev Med Brux; 1982 Apr; 3(4):209-16. PubMed ID: 7046007
[No Abstract] [Full Text] [Related]
54. Endocrine effects of adjuvant chemotherapy in premenopausal women: suggestions for the future.
Tormey DC
Recent Results Cancer Res; 1989; 115():106-12. PubMed ID: 2623329
[No Abstract] [Full Text] [Related]
55. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
56. Randomized perioperative therapy in operable breast cancer: the Ludwig Trial V.
Goldhirsch A; Gelber RD
Recent Results Cancer Res; 1989; 115():43-53. PubMed ID: 2696040
[No Abstract] [Full Text] [Related]
57. Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer.
Ingle JN; Everson LK; Wieand HS; Martin JK; Votava HJ; Wold LE; Krook JE; Cullinan SA; Paulsen JK; Twito DI
J Clin Oncol; 1988 Sep; 6(9):1388-96. PubMed ID: 3047333
[TBL] [Abstract][Full Text] [Related]
58. Adjuvant chemotherapy for operable breast cancer with positive axillary nodes: a comparison of CMFVP versus L-PAM.
Rivkin SE; Glucksberg H; Foulkes M; Osborne CK; Tranum W; Gad-el-Mawla N; Constanzi J
World J Surg; 1985 Oct; 9(5):719-22. PubMed ID: 3840628
[No Abstract] [Full Text] [Related]
59. The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation.
Levine MN; Bramwell V; Abu-Zahra H; Goodyear MD; Arnold A; Findlay B; Skillings J; Gent M
Br J Cancer; 1992 Jan; 65(1):130-2. PubMed ID: 1733435
[TBL] [Abstract][Full Text] [Related]
60. [Recent advance in adjuvant therapy for breast cancer].
Shimizu C; Watanabe T
Gan To Kagaku Ryoho; 2002 Dec; 29(13):2458-69. PubMed ID: 12506467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
